Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study

BACKGROUND: Patients with intermediate to advanced hepatocellular carcinoma (HCC) are most commonly treated with transarterial chemoembolization (TACE). Previous studies showed that TACE combined with recombinant human adenovirus type 5 (H101) may provide a clinical survival benefit. In the present...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Chao-Bin, Lao, Xiang-Ming, Lin, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518415/
https://www.ncbi.nlm.nih.gov/pubmed/28728568
http://dx.doi.org/10.1186/s40880-017-0227-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518415/
https://www.ncbi.nlm.nih.gov/pubmed/28728568
http://dx.doi.org/10.1186/s40880-017-0227-2

Ejemplares similares